ArticleScientific reports2025
Impact of radiotherapy on survival outcomes in metastatic neuroblastoma a propensity score matched SEER database analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic neuroblastoma is a highly aggressive pediatric malignancy with poor prognosis. Radiotherapy is commonly used as part of multimodal treatment, but its impact on survival outcomes remains controversial. This study investigates the association between radiotherapy and survival in patients with metastatic neuroblastoma using data from the Surveillance, Epidemiology, and End Results (SEER) database. A retrospective analysis was conducted on 4,850 patients diagnosed with metastatic neuroblastoma from the SEER database (2004-2015). After applying exclusion criteria, 981 patients were included, with 368 receiving radiotherapy. Propensity score matching (PSM) was used to balance baseline characteristics between the radiotherapy and non-radiotherapy groups, resulting in 234 patients in each group. Survival outcomes were analyzed using Kaplan-Meier curves and Cox proportional hazards models. Before PSM, no significant difference in overall survival (OS) and cancer-specific survival (CSS) was observed between patients who received radiotherapy and those who did not. After PSM, there was a trend toward improved OS and CSS in the radiotherapy group, though statistical significance was not reached. Cox regression analysis identified age ≥ 1 year and non-adrenal primary tumor site as significant independent predictors of poorer OS and CSS. Radiotherapy was not an independent predictor of survival in the multivariate analysis, but a trend toward a survival benefit was noted, particularly in patients with larger tumors and those who underwent surgery. Radiotherapy may improve survival in metastatic neuroblastoma patients with large tumors or surgical resection, though its independent benefit remains uncertain. Personalized strategies require integrating updated COG risk stratification with biomarkers and prospective trials assessing long-term outcomes to refine treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.